P
atients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) are at high risk for invasive fungal disease, in particular, for invasive aspergillosis (1) (2) (3) . Despite the availability of new antifungal compounds, the mortality rate for invasive aspergillosis reaches up to 70% in this patient population (4, 5) . While severe and prolonged neutropenia is the single most important risk factor for invasive aspergillosis, it has become clear that also adaptive immunity, in particular, the T helper (T H ) cell population, plays a critical role in the host response to Aspergillus (6) . In this regard, the majority of invasive aspergillosis occurs in HSCT recipients at a time when neutropenia has generally resolved but adaptive immune responses are still hampered (4, 7) . Since the presence of T H 1 lymphocytes correlates with a favorable outcome of invasive aspergillosis (8) , it was speculated that adoptive transference of donor-derived anti-Aspergillus T H 1 cells to HSCT recipients will improve the prognosis of the infection. In fact, a small study of 10 allogeneic transplant recipients suffering from invasive aspergillosis demonstrated that the adoptive transfer of specific in vitro-generated anti-Aspergillus T H 1 cells resulted in a clinical benefit (9); 9 out of the 10 patients who had received anti-Aspergillus T H 1 cells cleared the infection and survived, whereas 6 out of 13 patients not receiving immunotherapy died due to invasive aspergillosis. Unfortunately, allogeneic HSCT recipients often require immunosuppressive agents as prophylaxis or treatment of graft-versus-host disease (GvHD). These compounds further increase the risk for invasive fungal disease, since they may have multiple negative effects on different arms of the immune system. For example, glucocorticosteroids not only suppress the phagocytic function of monocytes and neutrophils but also may impair antigen presentation, T cell function, and the expression of proinflammatory cytokines (10) . However, data on the effect of various dosages of immunosuppressive compounds on the functional properties of anti-Aspergillus T H 1 cells are lacking, which, in turn, has an important impact on the adoptive immunotherapeutic approach of using anti-Aspergillus T H 1 cells. We therefore assessed the effect of commonly used immunosuppressive agents on important functional properties of anti-Aspergillus T H 1 cells, such as proliferation and cytokine secretion.
(Part of this work was presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy [ICAAC], Denver, CO, 10 to 13 September 2013.)
MATERIALS AND METHODS
Study subjects. A total of 200 ml peripheral blood obtained from healthy volunteers (n ϭ 8) was used for the generation of anti-Aspergillus T H 1 cells. None of the individuals had a history of invasive fungal infection or had received any medication within 4 weeks of the blood draw. The protocol was approved by the local ethics committee.
Fungal antigens. The water-soluble cellular extract of Aspergillus fumigatus (strain CBS 144-89) was prepared as described before and stored in aliquots at Ϫ80°C (11). The extract was tested for sterility and endotoxin concentration.
Immunosuppressive compounds. The immunosuppressive compounds cyclosporine (CsA; Novartis Pharma, Nuremberg, Germany), methylprednisolone (Sanofi Aventis, Frankfurt, Germany), mycophenolic acid (MPA; Sigma-Aldrich, Steinheim, Germany), the active component of mycophenolate mofetil (MMF), and rapamycin (Pfizer, New York, NY, USA) were obtained commercially. All agents were stored and dissolved according to the manufacturers' instructions. At least three concentrations were tested for each compound. In addition to testing the concentrations reflecting common target levels in serum (e.g., 0.1 to 0.15 g/ml for CsA, 1 to 3.5 g/ml for MPA, and 0.001 to 0.02 g/ml for rapamycin) or concentrations based on pharmacokinetic data and common dose recommendations (e.g., 2 mg of methylprednisolone/kg of body weight/day) (12-15), we evaluated each compound in significantly lower and higher concentrations. Specifically, MPA was used at concentrations of 0.5, 5.0, and 50 g/ml, methylprednisolone at 0.025, 0.25, and 2.5 g/ml, rapamycin at 0.001, 0.01, and 0.1 g/ml, and CsA at 0.000015, 0.00015, 0.005, 0.0015, 0.03, 0.15, and 0.75 g/ml.
Generation of anti-Aspergillus T H 1 cells. Anti-Aspergillus T cells were enriched and cultivated as previously described, with some modifications (16) . Briefly, peripheral blood mononuclear cells (PBMCs) were isolated by means of Ficoll-Paque density gradient centrifugation, incubated for up to 16 h with antigens of A. fumigatus (7.5 g/ml), and coincubated with monoclonal antibodies (MAbs) against CD40 (Miltenyi Biotech, Bergisch-Gladbach, Germany). Then, activated CD4 ϩ T cells were isolated using the CD154 MicroBead kit (Miltenyi Biotech), followed by a cultivation period of up to 14 days using cytotoxic T lymphocyte (CTL) medium containing RPMI 1640, 100 IU/ml penicillin G, 100 mg/ml streptomycin (Life Technologies, Darmstadt, Germany), and 10% pooled heat-inactivated human serum. Cells were cultivated in the presence of recombinant human interleukin 2 (rhIL-2) (50 U/ml; Chiron, Ratingen, Germany) and restimulated twice during the culturing period using irradiated autologous Aspergillus antigen-loaded antigen-presenting cells (APCs), which were obtained from PBMCs by the adherence method as described previously in detail (16) . Cultivated cells were restimulated again for 2 h using Aspergillus antigen-loaded APCs. Then, a second purification and expansion step was performed by means of the gamma interferon (IFN-␥) cytokine secretion assay (CSA; Miltenyi Biotech), followed by rapid expansion for up to 7 days as previously described (16) .
Phenotypic and functional analyses of generated anti-Aspergillus T H 1 cells. Generated cells were phenotypically characterized by means of flow cytometry using MAbs against CD3, CD4, CD8, CD14, CD19, CD56, CD69, human leukocyte antigen DR (HLA-DR), and 7-amino-actinomycin D (7-AAD) and a FACSCanto II flow cytometer (BD Biosciences, San Jose, CA, USA).
The viability of anti-Aspergillus T H 1 cells was estimated by 7-AAD staining and flow cytometry. Apoptosis and cell death were analyzed by means of flow cytometry using annexin V and propidium iodide (PI) staining (BD Biosciences) after 24 h of coincubation with and without the immunosuppressive agent. Cell numbers were assessed using trypan blue staining and conventional microscopy.
Functional analyses of anti-Aspergillus T H 1 cells, such as proliferation and cytokine production upon restimulation, were performed in the absence and presence of the different immunosuppressive agents. The percentage of cytokine-producing cells was assessed by means of the intracellular cytokine cytometry (ICC) assay as described previously (16) . In brief, anti-Aspergillus T H 1 cells were stimulated with autologous antigen-loaded APCs (effector/stimulator cell ratio, 5:1) and coincubated with the MAbs CD28 (BD Biosciences) and CD49d (Coulter Immunotech) (2 g/ml each) for 6 h. Brefeldin A (10 g/ml; Sigma, Deisenhofen, Germany) was added for the last 5 h. Finally, cells were permeabilized and stained using MAbs against IFN-␥, tumor necrosis factor alpha (TNF-␣), CD3, CD4, CD62L, CD45RO, and CD154 (BD Biosciences). Negative controls were performed using unloaded autologous APCs; cells stimulated with phorbol-12-myristate-13-acetate (PMA; 0.5 g/ml; Sigma) and ionomycin (1 g/ml; Sigma) served as positive controls.
The proliferation of anti-Aspergillus T H 1 cells was assessed by means of the carboxyfluorescein diacetate succinimidyl ester (CFSE) labeling assay (Molecular Probes, Eugene, OR, USA) as described before (16) . Briefly, cells were CFSE labeled and cultivated in CTL medium for 6 days. After additional staining with MAbs against CD3, CD4, and HLA-DR, the percentages of proliferating cells were estimated on days 3 and 6 by flow cytometry.
Assessment of cytokine concentration. Cytokine levels were measured in the supernatant obtained on day 3 of the CFSE assay. Concentrations were assessed by means of the cytometric bead array (CBA; BD Biosciences) according to the manufacturer's instructions. The lower level of detection was 1.4 pg/ml for IL-4 and 0.8 pg/ml for IFN-␥.
Statistical analyses. Data were analyzed using GraphPad Prism (version 5.04 for Windows; GraphPad Software, San Diego, CA, USA) and compared with the paired t test. A two-sided P of Ͻ0.05 was considered to be statistically significant. Since the generation of Aspergillus-specific T cells did not always result in a sufficient number of cells, the numbers of experiments occasionally differed. CsA, methylprednisolone, and MPA result in a significantly reduced number of anti-Aspergillus T H 1 cells in the cell culture. The efficacy of adoptively transferred anti-Aspergillus T H 1 cells depends on the number of viable and functionally active effector cells. After 6 days of culture, the number of viable anti-Aspergillus T H 1 cells was significantly lower when cells were coincubated with methylprednisolone and MPA than when they were left untreated (controls) (P Ͻ 0.05 in each case) ( Fig. 1 and see Fig. S1 in the supplemental material). Similarly, CsA at dosages of 0.03, 0.15, and 0.75 g/ml resulted in significantly lower numbers of viable anti-Aspergillus T H 1 cells than in the control (P Ͻ 0.05 each) ( Fig.  1 and S1 ). Whereas CsA at a dosage of 0.0015 g/ml decreased the number of viable anti-Aspergillus T H 1 cells in the culture by approximately 50%, CsA at concentrations of 0.0005 g/ml and lower revealed no effect (Fig. S2) . In contrast, none of the dosages of rapamycin tested had a significant impact on the cell number (Fig. 1) .
RESULTS

Number and phenotypic characterization of generated anti-
Since reduced cell numbers in the culture may be the result of a decreased proliferation and/or an increased rate of apoptosis, we evaluated both the proliferation and the apoptosis of anti-Aspergillus T H 1 cells. Whereas approximately 90% of the anti-Aspergillus T H 1 cells of the control cultivated in the absence of immunosuppressants underwent at least one cell cycle (median [range], 88% [46% to 98%]), methylprednisolone and MPA significantly reduced the proliferation of anti-Aspergillus T H 1 cells (P Ͻ 0.05 in each case) ( Fig. 2 and see Fig. S3 in the supplemental material) . Notably, the strongest inhibition of proliferation was seen for MPA at dosages of 5 and 50 g/ml. MPA did not significantly alter the rate of apoptosis of anti-Aspergillus T H 1 cells, whereas apoptosis of the cells was increased by methylprednisolone; a statistically significant increase was seen for doses of 0.025 and 2.5 g/ml (P Ͻ 0.05 in each case) ( Fig. 3 and S4) . Similarly, CSA dosages of 0.03 g/ml and higher significantly decreased the proliferative response of anti-Aspergillus T H 1 cells (P Ͻ 0.05 in each case) (Fig.  2) , whereas CsA at concentrations of 0.0005 g/ml and lower did not affect the proliferation (Fig. S5) . CsA did not have a major impact on apoptosis (Fig. 3) . In contrast to the other immunosuppressants evaluated, rapamycin did not significantly affect the proliferation and apoptosis of anti-Aspergillus T H 1 cells ( Fig. 2 and  3 ; see also Fig. S3 and S4 ). For all immunosuppressants tested, the effects on proliferation were similar when assessed at day 3 and at day 6 (data not shown).
CsA significantly decreases the percentage of IFN-␥-producing anti-Aspergillus T H 1 cells and concentrations of IFN-␥ in the supernatant. Since IFN-␥ is an important molecule for the antifungal activity of anti-Aspergillus T H 1 cells, we evaluated the impact of immunosuppressants on the percentage of IFN-␥-producing cells as well as on IFN-␥ levels in the supernatant. Compared to no treatment, CsA at dosages of 0.03 g/ml and higher significantly reduced both the percentage of IFN-␥-producing antiAspergillus T H 1 cells and the IFN-␥ levels (P Ͻ 0.05 in each case) (Fig. 4 and 5) . Dilution experiments revealed that CsA at a dosage of 0.0005 g/ml resulted in an inhibition of approximately 50% of IFN-␥ production, whereas CsA at concentrations of 0.00015 g/ml and lower did not affect IFN-␥ production (see Fig. S6 in the supplemental material). Whereas none of the other immuno- suppressants tested significantly impacted the number of IFN-␥-producing cells (with the exception of the highest dosage of MPA) (Fig. 4) , a significant decrease in the concentration of IFN-␥ in the supernatant was detected for all dosages of methylprednisolone as well as for higher dosages of MPA and rapamycin (P Ͻ 0.05 in each case) (Fig. 5) . However, this impact was considerably less pronounced than the effect by CsA. For all immunosuppressants tested, the effects on IFN-␥ production were similar when assessed at day 3 and at day 6 (data not shown).
CsA negatively influences the expression of the antigen-specific activation marker CD154. Since CD154 is an important regulatory molecule in host immunity, we evaluated the impact of immunosuppressive compounds on this specific marker for antigen-activated T helper cells. At dosages of 0.03 g/ml and higher, CsA significantly decreased the percentage of CD154-expressing T cells compared to the percentages in controls (P Ͻ 0.05 each) ( Fig.  6 and see Fig. S7 in the supplemental material), whereas a decrease of approximately 50% of the CD154-expressing cells was seen at a dosage of 0.0005 g/ml. CsA at dosages of 0.00015 g/ml and lower did not have a relevant impact on CD154 expression (Fig.  S8) . A slight but significant increase in the percentage of CD154-expressing cells was seen for the highest dosages of MPA, whereas none of the other dosages of the immunosuppressants methylprednisolone and rapamycin tested affected the CD154 expression of anti-Aspergillus T H 1 cells (Fig. 6 and S7 ).
DISCUSSION
CsA, methylprednisolone, MMF, and rapamycin are commonly used immunosuppressants in the allogeneic HSCT setting for the prevention of graft rejection and the prophylaxis and treatment of GvHD. In the present study, we evaluated for the first time the effects of these immunosuppressants on important functional properties of specific anti-Aspergillus T H 1 cells. These analyses are important since the beneficial effects of adoptively transferred anti-Aspergillus T H 1 cells, which has been demonstrated in a pivotal clinical trial in HSCT recipients suffering from invasive aspergillosis (9), may be compromised or even abolished by the concomitant use of immunosuppressants. Our results demonstrate that different dosages of the immunosuppressants tested have particular effects on cell proliferation and/or the upregulation of important effector molecules, such as IFN-␥ and CD154 of anti-Aspergillus T H 1 cells (10) . Although several previous studies have evaluated the influence of immunosuppressive compounds on lymphocytes, our studies are novel and important, since older studies either investigated bulk lymphocytes/PBMCs, which may exhibit functional properties different from those of antigen-specific T cells, or investigated CD8 ϩ T cells specific for cytomegalovirus (CMV) or Epstein-Barr virus (EBV) stimulated with nonphysiologic stimuli, such as ionomycin. It has also to be noted that the present, rather complex approach to generating Aspergillusspecific T cells was not designed for generating cells for a clinical trial but was needed to generate extremely large numbers of Aspergillus-specific cells required for the experiments. Importantly, the present approach results in the generation of a highly homogenous cell population which has phenotypic characteristics and functionality comparable to those of cells suitable for a clinical trial (16, 17) . Although the anti-Aspergillus T H 1 cells that result in a clinical benefit have been generated with a strategy different from that used for the anti-Aspergillus T H 1 cells in the present study (9) , similar functional properties suggest that the cells used in the present study also exhibit a therapeutic effect.
CsA inhibits calcineurin, which is activated through T cell receptor signaling and leads to dephosphorylation of the nuclear factor of activated T cells (NFATc). Dephosphorylated NFATc is required for the transcription of several key genes for T cell activation, differentiation, and proliferation, such as the IFN-␥, TNF-␣, or IL-2 gene (18) . Therefore, it is not surprising that CsA at dosages higher than 0.0015 g/ml significantly reduced the number of cultivated anti-Aspergillus T H 1 cells, which was caused mainly by the inhibition of proliferation. This observation is important, since the efficacy of adoptively transferred anti-Aspergillus T H 1 cells depends on the number of viable and functionally active effector cells. Unfortunately, due to the low percentages of anti-Aspergillus T H 1 cells in the peripheral blood of healthy individuals, clinical-scale isolation strategies result in a limited number of isolated anti-Aspergillus T H 1 cells (19) . On the other hand, in vitro data clearly demonstrate that the isolated anti-Aspergillus T H 1 cells are not end differentiated and are able to proliferate when restimulated by a naturally processed antigen (19) . This corroborates the in vivo observation for haploidentical transplant recipients in whom increasing numbers of anti-Aspergillus T H 1 cells were found within 3 weeks of adoptive transfer of the donorderived cells (9) . Therefore, our data suggest that the concomitant use of CsA with adoptively transferred donor-derived anti-Aspergillus T H 1 cells may result in an insufficient number of effector cells in vivo. In addition, our results show that CsA in subtherapeutic levels significantly inhibited the production of IFN-␥ upon restimulation with naturally processed Aspergillus antigens, which is in line with recently reported data on purified memory CD4 ϩ T cells stimulated with PMA and ionomycin (20) , as well as with data on CMV-specific CD8 ϩ T cells (21) . This is an important observation, since IFN-␥ is well known as one of the key molecules in the combat against Aspergillus (6) . In clinical settings, it has been demonstrated that in patients with invasive aspergillosis, a predominant release of IFN-␥ in culture supernatants upon stimulation with A. fumigatus antigens is associated with a favorable outcome (8) . Our results also demonstrate that subtherapeutic levels of CsA significantly reduce the percentage of CD154-producing CD4 ϩ T cells, which corroborates previous results on unspecific CD4
ϩ T cells stimulated with PMA and ionomycin (22) . Notably, CD154, also known as CD40L, plays an important role in T cell-dependent B cell proliferation, memory cell formation, and B cell antibody response (23, 24) . Our results suggest that CsA should be avoided, whenever possible, in patients receiving adoptive immunotherapy with anti-Aspergillus T H 1.
MPA, the active component of MMF, is an inhibitor of the type II isoform of IMP dehydrogenase, which is involved in the synthesis of guanine nucleotides mandatory for cell proliferation (25) . This corroborates our results demonstrating that MPA significantly reduced the number of cultivated anti-Aspergillus T H 1 cells. In particular, MPA decreased proliferation at high dosages, whereas apoptosis was only slightly increased, and this increase did not reach statistical significance. A recent study reported on the negative impact of MPA on the proliferation of highly purified nonspecific CD4 Glucocorticosteroids are widely used immunosuppressants in the prevention and treatment of GvHD, and they exhibit their potent immunosuppressive effects by a number of mechanisms, such as the suppression of the transcription of various proinflammatory genes, the promotion of apoptosis of T cells, and the strong inhibition of the proliferation of specific T H 1 and T H 2 clones (10, 29, 30) . In line with this, we observed that methylprednisolone at dosages of 0.025 g/ml and 2.5 g/ml significantly increased both the rate of apoptosis and the rate of proliferation of anti-Aspergillus T H 1 cells. In addition, as with our results, a negative effect of glucocorticosteroids on IFN-␥ production was reported, which seems to be more pronounced for dexamethasone than for methylprednisolone (30, 31) . Since methylprednisolone is recommended for the treatment of acute GvHD and used by the majority of centers as a first-line treatment, we chose this compound for our analysis (32, 33) .
Rapamycin, an immunosuppressive macrolide, specifically inhibits mammalian target of rapamycin complex 1 (mTORC1), which plays an important role in the differentiation and function of T cells and dendritic cells (DCs) (34) . It was recently reported that rapamycin markedly reduced the proliferation of CD4 ϩ T cells (35) , in contrast to our results with anti-Aspergillus T H 1 cells. However, this discrepancy may be explained by different dosages of rapamycin, since Battaglia et al. (35) observed this effect only when using rapamycin at a dosage of 1 g/ml, a dosage 10-to 1,000-fold higher than the dosages that we used in our experiments. Similarly, others have reported only a weak inhibition of T cell activity with rapamycin concentrations lower than 0.1 g/ml (36), which was the highest dose in our setting. Notably, we used in our experiments the recommended target range of rapamycin in allogeneic HSCT recipients, which is between 0.001 and 0.02 g/ml (15) . However, it is also important to note that rapamycin exhibits its immunosuppressive activity by a variety of mechanisms on different cell populations, such as the induction of proliferation of immunosuppressive CD4 ϩ CD25 ϩ FOXP3 ϩ T regulatory cells or the In conclusion, we studied for the first time the effects of various commonly used immunosuppressants on important functional properties of anti-Aspergillus T H 1 cells, such as proliferation and IFN-␥ production, upon their restimulation with naturally processed antigens. Our in vitro data demonstrate that CsA, MPA, and methylprednisolone exhibit significant and particular effects on these functional properties, whereas our data did not exhibit a major impact of rapamycin on the generated antiAspergillus T H 1 cells. Although further studies are warranted to assess both newer immunosuppressants, such as anti-inflammatory antibodies, and the complex effects of immunosuppressants in vivo, our data may have an important impact on the design of clinical studies evaluating the effect of adoptively transferred antiAspergillus T H 1 cells to allogeneic HSCT recipients suffering from invasive aspergillosis.
ACKNOWLEDGMENT
This work was supported by the Uniscientia Stiftung.
